menu search

IOBT / IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study

IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study
IO Biotech (IOBT) falls 25% despite achieving the clinical milestone of enrolling 225 patients in the advanced melanoma study evaluating the IO102-IO103/Keytruda combo. Read More
Posted: Jun 15 2023, 09:32
Author Name: Zacks Investment Research
Views: 042160

IOBT News  

IO Biotech Announces Participation in Upcoming Investor Conferences

By GlobeNewsWire
September 6, 2023

IO Biotech Announces Participation in Upcoming Investor Conferences

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating more_horizontal

IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study

By Zacks Investment Research
June 15, 2023

IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study

IO Biotech (IOBT) falls 25% despite achieving the clinical milestone of enrolling 225 patients in the advanced melanoma study evaluating the IO102-IO1 more_horizontal

IO Biotech to Present at the Jefferies Healthcare Conference

By GlobeNewsWire
May 30, 2023

IO Biotech to Present at the Jefferies Healthcare Conference

NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating c more_horizontal


Search within

Pages Search Results: